Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


RCT Spells Requirement For Lipidryl, Shrinking Beauty Weight Loss Claims

This article was originally published in The Tan Sheet

Executive Summary

Although FTC orders for RCTs to substantiate claims are criticized by some industry stakeholders, the agency routinely includes the burden of clinical trials in settlements with firms found to conduct false and misleading advertising for consumer health products, particularly in the weight loss area.

You may also be interested in...

Trade Groups, Emord Rip FTC Interpretation Of POM Wonderful Ads

An amici curiae brief filed in the POM Wonderful case by CHPA and CRN criticizes FTC for relying “on its own ‘expertise’ to determine the meaning of ambiguous advertisements.” A separate brief by attorney Jonathan Emord says FTC is creating unreasonable barriers for food product research.

In Brief

NAD refers Solace to FTC; ERSP chastises TriVita for testimonials; Perrigo gains second China formula distributor; CHPA comments on lobbying regulations; Acetaminophen linked to asthma in children; CSPI pushes for St. John’s wort warning

Unprecedented To Lawful: Regulatory Precedent Needed For Cannabinoids’ Use In Supplements?

“This is truly uncharted territory because we’ve never had this situation,” says CHPA regulatory VP David Spangle. Asking Congress instead to instruct FDA to first determine a safe daily limit would be a threatening precedent for the supplement market, says CRN CEO Steve Mister. “That really turns DSHEA on its head.”





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts